|
|
Post by madog365 on Sept 5, 2018 9:57:11 GMT -5
Yesterday's deal with UT has put a serious valuation to Mannkind's technosphere technology. We are talking about almost $100m (upfront & milestones) in cash that will be paid to MNKD for a drug before it is even FDA approved.
Now when i hear Mike talk about almost 40 other molecules that are technosphere ready , you begin to understand the potential this company holds.
If i am a big pharma with drugs under patent that are potentially expiring (same as UT) and i hear that there might be a way to deliver them with an already approved FDA approved technology, i may be salivating at the chance to maintain my market share. Now i can pay mankind 100m to license just one drug or i can make a tender offer for the whole company which is currently trading around 400M market cap. Of course it will cost many multiples of that but that is a small price to pay when thinking about how much value technosphere can bring to a larger drug portfolio.
That's without afrezza, fda approved best in class diabetes treatment with 3b invested.
|
|
|
|
Post by peppy on Sept 5, 2018 10:01:24 GMT -5
Sanofi, NovoNordsk,Lilly, Pfizer, Merek, they know. We have been watching them sit on their hands for years.
Someone was going to snatch up the patents.
|
|
|
|
Post by madog365 on Sept 5, 2018 10:02:38 GMT -5
Sanofi, NovoNordsk,Lilly, Pfizer, Merek, they know. We have been watching them sit on their hands for years. Someone was going to snatch up the patents. Exactly why they are a buyout target now. IF they were waiting for BK sale, they just lost that opportunity. Now they see a low market cap company with tremendous upside. Bid now or pay much more later. |
|
|
|
Post by tinkusr8215 on Sept 5, 2018 10:08:49 GMT -5
Just got a life line to execute the plan and why are we talking about BO?
|
|
|
|
Post by madog365 on Sept 5, 2018 10:11:57 GMT -5
Just got a life line to execute the plan and why are we talking about BO? You can talk about whatever you want in another thread. My thoughts are Mannkind just became a very attractive potential asset at a currently discounted price point. |
|
|
|
Post by peppy on Sept 5, 2018 10:12:34 GMT -5
can we say Regeneron?
This stuff all typed about prior.
I believe Big Pharma is watching.
|
|
|
|
Post by scottmnkd on Sept 5, 2018 10:25:00 GMT -5
Sanofi, NovoNordsk,Lilly, Pfizer, Merek, they know. We have been watching them sit on their hands for years. Someone was going to snatch up the patents. Seems big pharma has been sitting back to see how successful Mike C and company will be prior to making a move. I wouldn't doubt it if one of those players, if not all, have been hoping for bankruptcy to get technosphere on the cheap. Now that it's becoming apparent that Mannkind will be successful, however, they'll need to bring a lot of cash to the table if they want to upgrade their portfolios. Being a stockholder since pre-approval has been extraordinary in terms of seeing the Mannkind story first hand. Remember, the stock traded for over $7 shortly after approval - that's over $35 given the reverse split. I've been able to pickup a lot more since then. We have a long ways to go on the upside before this ends. GLTA! |
|
|
|
Post by sr71 on Sept 5, 2018 11:23:30 GMT -5
I don't think Mike would be eager to sell the company, as Mannkind is just getting started on the road to massive success. I also believe he is shrewd enough to parlay potential buyout offers into lucrative partnership agreements instead, since the large pharma's are likely beginning to see that MNKD is not going to fail. Without BK or Buyout, partnerships are the only option left for big pharma to get in on the Technosphere action.
|
|
|
|
Post by mannmade on Sept 5, 2018 12:29:19 GMT -5
Does not need to be a buyout. As Peppy says and I have been telling Sports for the last few years.... best thing that could happen to Mannkind is a deal like Regeneron did with Sanofi. Last time I checked Regeneron stock was $405. And I believe they may have started their relationship with Sanofi similar to way mnkd has with United. We now have a big brother/sister to protect us from big pharma. And they seem to have a different kind of CEO who just may have the right combination of vision, drive, pathos and compassion that we need from a big brother... or sister... GLTAL’s!
|
|
|
|
Post by Chris-C on Sept 5, 2018 13:04:08 GMT -5
I suggest that yesterday was potentially but not absolutely a game changer. And I don't think a buyout is in Mike's strategic plan. There was a reason that the last earnings call was focused and confident, with no mention of dilution, and that is because everyone on the team knew that discussions were underway for this deal with United. It would not surprise me if there are also significant agreements being discussed with other companies for markets outside the USA and for development of other TS molecules. As soon as the road to profitability seems assured, there will be more buying and more market interest on the bullish side. The Fool's Feroldi wrote today that he was still skeptical about the company's overall success, which he has been since the beginning. He thinks the SP increase is mostly due to a short squeeze. Personally, I believe it will take more than yesterday's announcement to turn overall market sentiment in MNKD's favor. I don't think general sentiment has yet turned. That is, I don't think we've seen the true change in sentiment that would precipitate a full fledged short squeeze. I refer to Feroldi's own continuing skepticism as evidence of that. And those of us who are true longs make adjustments for the reverse split that substantially reduced our share counts. With that in mind, we are still substantially under $1.00 per share in my mind, so we have miles to go. The market has traders and it has investors...there is a difference. Patience is a friend of investors.
GLTAL
Chris C
|
|
|
|
Post by cedafuntennis on Sept 5, 2018 13:13:24 GMT -5
can we say Regeneron? This stuff all typed about prior. I believe Big Pharma is watching. Yes we can. My short time concern is with the warrants and putting a cap at around $2,38 (most probably under) for the next few months. What a drag with those. Could anyone mention quickly how many warrants are exercisable at that price? Besides that, I think that the genie is out of the bottle and the genie is Mike and his team. I am also very happy with the partner they chose as they have a relationship with Al Mann going back many, many years and shared mutual trust and respect. Forget SNY and learn from that negative experience as Mike did. |
|
|
|
Post by theshiv on Sept 5, 2018 13:22:06 GMT -5
Big pharma has been watching every single move MannKind has made for several years now. They are very well aware of the potential of this company. Having United step forward is very compelling and confirms the value of MNKD assets.
|
|
|
|
Post by mnholdem on Sept 5, 2018 14:30:46 GMT -5
There has always been a possibility that BP (including Sanofi) has been hoping MannKind would fail so they could bid pennies on the dollar for the intellectual property, whether to utilize it or shelf it.
|
|
|
|
Post by cretin11 on Sept 5, 2018 15:38:45 GMT -5
It actually traded for over $10 shortly after approval, which is over $50 given the reverse split. I remember well, since I still have shares at that price sitting in my portfolio. Have sold none, it's been all about lowering my average share price ever since... |
|
|
|
Post by sportsrancho on Oct 20, 2018 22:23:19 GMT -5
Does not need to be a buyout. As Peppy says and I have been telling Sports for the last few years.... best thing that could happen to Mannkind is a deal like Regeneron did with Sanofi. Last time I checked Regeneron stock was $405. And I believe they may have started their relationship with Sanofi similar to way mnkd has with United. We now have a big brother/sister to protect us from big pharma. And they seem to have a different kind of CEO who just may have the right combination of vision, drive, pathos and compassion that we need from a big brother... or sister... GLTAL’s! |
|
